Valneva Showcases Chikungunya Vaccine at World Vaccine Congress

An update from Valneva ( (VALN) ) is now available.

On April 16, 2025, Valneva announced its participation in the 25th World Vaccine Congress, held from April 21-24, 2025, in Washington, D.C. The company will present its chikungunya vaccine, IXCHIQ®, the world’s first licensed vaccine for this disease, and is a finalist for two awards at the Vaccine Industry Excellence Awards. Valneva’s involvement in the congress highlights its strategic focus on addressing significant public health challenges and reinforces its position as a leader in the vaccine industry.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

Valneva’s stock score reflects a company with improving financial metrics but still facing profitability hurdles. The technical analysis indicates some positive long-term momentum, but valuation concerns persist due to negative earnings. The earnings call provides a balanced outlook with both optimistic guidance and notable challenges. These factors combined suggest moderate potential, but with significant risks.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from early R&D to approvals. Valneva markets three proprietary travel vaccines, including the world’s first chikungunya vaccine, and has a growing pipeline that includes a Lyme disease vaccine candidate in partnership with Pfizer.

YTD Price Performance: 49.36%

Average Trading Volume: 84,869

Technical Sentiment Signal: Hold

Current Market Cap: $604.2M

For detailed information about VALN stock, go to TipRanks’ Stock Analysis page.